Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMAD R BOLOURI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1659322691
CMS profile
29086
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$3,758.34

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,402.00 2
Food and Beverage $356.34 13

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Biogen, Inc. $3,570.98 4
Lilly USA, LLC $59.47 4
Corium, LLC $52.30 3
Avanir Pharmaceuticals, Inc. $38.70 2
Neurocrine Biosciences, Inc. $36.89 2

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMAD R BOLOURI

NPI 1659322691 · CMS profile ID 29086

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659322691?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659322691?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659322691?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1659322691?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $3,758.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $133.9511/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923408185 CMS
Lilly USA, LLC $14.5111/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918208419 CMS
Corium, LLC $19.6311/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924848117 CMS
Corium, LLC $17.1310/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924848115 CMS
Corium, LLC $15.5409/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924848113 CMS
Biogen, Inc. $35.0309/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923441481 CMS
Neurocrine Biosciences, Inc. $15.5909/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963438095 CMS
Lilly USA, LLC $13.7808/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918207629 CMS
Neurocrine Biosciences, Inc. $21.3008/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963437973 CMS
Avanir Pharmaceuticals, Inc. $18.9906/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935954437 CMS
Lilly USA, LLC $16.0706/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918232285 CMS
Avanir Pharmaceuticals, Inc. $19.7104/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935943953 CMS
Lilly USA, LLC $15.1103/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918186379 CMS
Biogen, Inc. $1,134.0003/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923393425 CMS
Biogen, Inc. $2,268.0001/03/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923397391 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,343.30 32
PY2020 $733.57 2
PY2021 $39.36 2
PY2022 $3,758.34 15
PY2023 $10,255.80 39
PY2024 $25,153.09 51
PY2025 $8,393.72 33

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,948,171.02 223
PY2024 Recipient $42,149.90 1
PY2024 Principal investigator $2,006,224.93 95
PY2023 Recipient $150.00 1
PY2023 Principal investigator $3,166,315.18 100
PY2022 Recipient $250.00 1
PY2022 Principal investigator $2,451,442.73 165
PY2021 Principal investigator $2,459,911.12 123
PY2020 Recipient $1,077.94 1
PY2020 Principal investigator $1,535,993.16 168
PY2019 Principal investigator $1,981,815.06 222

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

123 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $34.76 12/31/2021 Non-covered Recipient Entity
AMC RESEARCH, LLC
A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer s Disease Dementia No dispute reported 06/30/2026 848742289
Principal investigator 1 Merck Sharp & Dohme Corporation $62.26 12/31/2021 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 848764419
Principal investigator 1 Eisai Inc. $26,152.20 12/20/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163905
Principal investigator 1 Eisai Inc. $27,460.80 12/20/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163913
Principal investigator 1 Eisai Inc. $8,115.00 12/01/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850647875
Principal investigator 1 Genentech, Inc. $8,475.00 11/26/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB OPEN LABEL EXTENSION No dispute reported 06/30/2026 835936563
Principal investigator 1 Genentech, Inc. $5,694.00 11/26/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
POSTGRADUATE ROLL OVER STUDY No dispute reported 06/30/2026 835936569
Principal investigator 1 Eisai Inc. $15,354.00 11/19/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163901
Principal investigator 1 Eisai Inc. $79,433.20 11/19/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163909
Principal investigator 1 Eisai Inc. $1,387.00 11/19/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164051
Principal investigator 1 Eisai Inc. $1,387.00 11/19/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164053
Principal investigator 1 Eisai Inc. $1,387.00 11/19/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164055
Principal investigator 1 Eisai Inc. $2,967.00 11/19/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164057
Principal investigator 1 Eisai Inc. $2,904.00 11/19/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164059
Principal investigator 1 Eisai Inc. $1,387.00 11/19/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164061
Principal investigator 1 Genentech, Inc. $32,151.00 11/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 835936557
Principal investigator 1 Eisai Inc. $36,611.10 11/05/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163917
Principal investigator 1 Eisai Inc. $2,600.00 11/01/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850647869
Principal investigator 1 Novo Nordisk AS $1,200.00 10/27/2021 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 811776197
Principal investigator 1 Novo Nordisk AS $3,000.00 10/27/2021 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 811870449
Principal investigator 1 Novo Nordisk AS $1,200.00 10/27/2021 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 811870451
Principal investigator 1 Eisai Inc. $10,988.10 10/20/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163899
Principal investigator 1 Eisai Inc. $34,845.30 10/20/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163915
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163977
Principal investigator 1 Eisai Inc. $2,912.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163979
Principal investigator 1 Eisai Inc. $1,442.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163981
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163983
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163985
Principal investigator 1 Eisai Inc. $1,481.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163987
Principal investigator 1 Eisai Inc. $1,442.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163989
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163991
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163993
Principal investigator 1 Eisai Inc. $1,442.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163995
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163997
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163999
Principal investigator 1 Eisai Inc. $1,498.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164001
Principal investigator 1 Eisai Inc. $632.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164003
Principal investigator 1 Eisai Inc. $2,912.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164005
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164007
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164009
Principal investigator 1 Eisai Inc. $1,498.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164011
Principal investigator 1 Eisai Inc. $1,442.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164013
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164015
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164017
Principal investigator 1 Eisai Inc. $1,481.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164019
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164021
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164023
Principal investigator 1 Eisai Inc. $1,442.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164025
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164027
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164029
Principal investigator 1 Eisai Inc. $1,442.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164031
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164033
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164035
Principal investigator 1 Eisai Inc. $1,481.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164037
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164039
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164041
Principal investigator 1 Eisai Inc. $1,442.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164043
Principal investigator 1 Eisai Inc. $632.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164045
Principal investigator 1 Eisai Inc. $826.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164047
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164049
Principal investigator 1 Eisai Inc. $7,800.00 10/01/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850647857
Principal investigator 1 Eisai Inc. $6,000.00 10/01/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850647863
Principal investigator 1 Eisai Inc. $39,248.10 09/24/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163903
Principal investigator 1 Eisai Inc. $9,347.40 09/22/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163897
Principal investigator 1 Eisai Inc. $2,296.00 09/17/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163971
Principal investigator 1 Eisai Inc. $2,904.00 09/17/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163973
Principal investigator 1 Eisai Inc. $2,296.00 09/17/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163975
Principal investigator 1 Eisai Inc. $1,033.20 09/17/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836164063
Principal investigator 1 Genentech, Inc. $55,435.00 08/25/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 835936551
Principal investigator 1 Eisai Inc. $5,109.30 08/20/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163907
Principal investigator 1 Eisai Inc. $37,949.40 08/20/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163911
Principal investigator 1 Genentech, Inc. $1,138.00 08/20/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
POSTGRADUATE ROLL OVER STUDY No dispute reported 06/30/2026 835936539
Principal investigator 1 Genentech, Inc. $3,760.00 08/20/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB OPEN LABEL EXTENSION No dispute reported 06/30/2026 835936545
Principal investigator 1 Genentech, Inc. $2,352.00 08/02/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
HCRU AMONG MEDICARE ENROLLED PTS PARTICIPATING IN SPONSOR CONDUCTED PHASE III CLINICAL TRIALS IN AD No dispute reported 06/30/2026 835936481
Principal investigator 1 Eisai Inc. $3,858.30 07/26/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163889
Principal investigator 1 Eisai Inc. $44,045.10 07/20/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163895
Principal investigator 1 Novo Nordisk AS $6.26 07/20/2021 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 811776195
Principal investigator 1 Novo Nordisk AS $180.64 07/20/2021 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 811893365
Principal investigator 1 Eli Lilly and Company $1,151.60 07/09/2021 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819450643
Principal investigator 1 Genentech, Inc. $2,500.00 07/01/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
HCRU AMONG MEDICARE ENROLLED PTS PARTICIPATING IN SPONSOR CONDUCTED PHASE III CLINICAL TRIALS IN AD No dispute reported 06/30/2026 835936475
Principal investigator 1 Eisai Inc. $1,442.00 06/25/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163951
Principal investigator 1 Eisai Inc. $1,387.00 06/25/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163953
Principal investigator 1 Eisai Inc. $1,552.00 06/25/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163955
Principal investigator 1 Eisai Inc. $2,352.00 06/25/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163957
Principal investigator 1 Eisai Inc. $2,904.00 06/25/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163959
Principal investigator 1 Eisai Inc. $1,442.00 06/25/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163961
Principal investigator 1 Eisai Inc. $1,387.00 06/25/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163963
Principal investigator 1 Eisai Inc. $1,387.00 06/25/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163965
Principal investigator 1 Eisai Inc. $1,552.00 06/25/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163967
Principal investigator 1 Eisai Inc. $2,296.00 06/25/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163969
Principal investigator 1 Genentech, Inc. $1,500.00 06/09/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
SC PROOF OF EFFICACY STUDY No dispute reported 06/30/2026 835936533
Principal investigator 1 Eli Lilly and Company $50.00 05/31/2021 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819465887
Principal investigator 1 Genentech, Inc. $36,971.00 05/17/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 835936528
Principal investigator 1 Genentech, Inc. $8,159.00 05/05/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB OPEN LABEL EXTENSION No dispute reported 06/30/2026 835936521
Principal investigator 1 Eli Lilly and Company $50.00 04/30/2021 Non-covered Recipient Entity
FAMILY MEDICAL ASSOCIATES
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819458411
Principal investigator 1 Genentech, Inc. $1,460.39 04/28/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 835936509
Principal investigator 1 Genentech, Inc. $6,470.00 04/28/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 835936515
Principal investigator 1 Genentech, Inc. $60,572.00 04/21/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 835936503
Principal investigator 1 Eisai Inc. $1,481.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163919
Principal investigator 1 Eisai Inc. $1,387.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163921
Principal investigator 1 Eisai Inc. $1,442.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163923
Principal investigator 1 Eisai Inc. $1,387.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163925
Principal investigator 1 Eisai Inc. $1,387.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163927
Principal investigator 1 Eisai Inc. $1,552.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163929
Principal investigator 1 Eisai Inc. $2,352.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163931
Principal investigator 1 Eisai Inc. $2,904.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163933
Principal investigator 1 Eisai Inc. $1,387.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163935
Principal investigator 1 Eisai Inc. $1,387.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163937
Principal investigator 1 Eisai Inc. $1,387.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163939
Principal investigator 1 Eisai Inc. $1,387.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163941
Principal investigator 1 Eisai Inc. $1,481.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163943
Principal investigator 1 Eisai Inc. $1,387.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163945
Principal investigator 1 Eisai Inc. $1,387.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163947
Principal investigator 1 Eisai Inc. $1,387.00 03/31/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163949
Principal investigator 1 Eisai Inc. $25,634.70 03/10/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163893
Principal investigator 1 Genentech, Inc. $60,653.00 02/17/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 835936499
Principal investigator 1 Genentech, Inc. $1,920.00 02/10/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB OPEN LABEL EXTENSION No dispute reported 06/30/2026 835936493
Principal investigator 1 Eli Lilly and Company $18,811.11 01/26/2021 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819450939
Principal investigator 1 Biogen, Inc. $571,351.00 01/14/2021 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 828999099
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,991.00 01/14/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A 5 YEAR PROSPECTIVE STUDY OF AN ANTI AMYLOID THERAPY CAD106 OR CNP520 IN SLOWING AND OR POSTPONING COGNITIVE DECLINE IN ASYMPTOMATIC APOE 4 HOMOZYGOTES AT RISK FOR DEVELOPING ALZHEIMERS DISEASE DEMENTIA No dispute reported 06/30/2026 800620751
Principal investigator 1 Genentech, Inc. $790.00 01/13/2021 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 835936487
Principal investigator 1 Eisai Inc. $16,146.90 01/06/2021 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 836163891
Principal investigator 1 Eli Lilly and Company $1,017,205.00 01/05/2021 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819450815